American Society of Hirudotherapy

Bloodsucking Leech FBN1 / GLB3 Expansion (Comparative)

Expanded FBN1 (fibrillin-1) + GLB3 (globin-3) gene families across H. nipponia / H. manillensis vs W. pigra — Zheng 2023 functional-genomic comparison.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 28, 2026 · ASH Editorial · based on the books

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound

Clinical translation limit

FBN1 / GLB3 expansion is a comparative-genomics finding with no direct human therapeutic translation. No FDA-approved derivative.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Source species
H. nipponia + H. manillensis vs W. pigra
Discovered
2023 · Zheng J et al.

Biological Targets

  • → FBN1: rapid post-feeding body swelling; GLB3: long-term blood storage in leech midgut

Key Citations

  1. Zheng J et al. (2023), Gigascience · PMID 37039117

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.